Weiss Ratings Reaffirms "Sell (D-)" Rating for 111 (NASDAQ:YI)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for 111 (NASDAQ:YI) in a research note issued to investors.
• 111, Inc. recently reported earnings of ($0.20) per share with revenues of $486.35 million for the last quarter.
• Connor Clark & Lunn Investment Management Ltd. acquired 11,338 shares of 111 stock, bringing institutional ownership to 21.32% of the company's stock.

111 (NASDAQ:YI - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities research analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

111 Price Performance

Shares of YI stock opened at $5.92 on Friday. The company has a market cap of $51.17 million, a price-to-earnings ratio of -9.25 and a beta of 0.46. 111 has a 1 year low of $4.14 and a 1 year high of $11.90. The firm has a fifty day moving average price of $6.84 and a 200-day moving average price of $7.65.

111 (NASDAQ:YI - Get Free Report) last released its earnings results on Thursday, June 19th. The company reported ($0.20) earnings per share for the quarter. The company had revenue of $486.35 million during the quarter.

Institutional Trading of 111

An institutional investor recently bought a new position in 111 stock. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of 111, Inc. Sponsored ADR (NASDAQ:YI - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 11,338 shares of the company's stock, valued at approximately $92,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.13% of 111 as of its most recent SEC filing. Institutional investors own 21.32% of the company's stock.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.